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ABSTRACT
Aim: Maintenance treatment in ulcerative colitis should
be as convenient as possible, to increase the chance of
compliance. MMX mesalazine is a once-daily, high-
strength (1.2 g/tablet) formulation of 5-aminosalicylic
acid. This study evaluated the safety and efficacy of MMX
mesalazine dosed once or twice daily as maintenance
therapy in patients with ulcerative colitis.
Methods: This multicentre, randomised, open-label trial
enrolled patients with strictly defined clinical and
endoscopic remission, immediately following an episode
of mild to moderate ulcerative colitis. Patients were
randomised to MMX mesalazine 2.4 g/day as a single
(261.2 g tablet) or divided dose (161.2 g tablet twice
daily) for 12 months.
Results: 174 patients (37.9%; safety population n=459)
experienced 384 adverse events, the majority of which
were mild or moderate in intensity. Eighteen patients
(3.9%), nine in each group, experienced a total of 22
serious adverse events (10 in the once-daily and 12 in the
twice-daily group). Most serious adverse events were
gastrointestinal, experienced by 5 patients in the once-
daily and 4 in the twice-daily group. At month 12, 64.4%
(efficacy population, n=451) of patients in the once-daily
and 68.5% of patients in the twice-daily group were in
clinical and endoscopic remission (p=0.351). At month
12, 88.9% and 93.2% in each group, respectively, had
maintained clinical remission (were relapse free).
Conclusions: MMX mesalazine 2.4 g/day administered
as a single or divided dose demonstrated a good safety
profile, was well tolerated and was effective as
maintenance treatment. High clinical and endoscopic
remission rates can be achieved with once-daily dosing.
Trial registration number: NCT00151944.
Mesalazine (5-aminosalicylic acid; 5-ASA), is the
standard therapy for maintaining remission in
ulcerative colitis (UC).
12Although currently avail-
able mesalazine preparations have been shown to
maintain remission, many patients are poorly
compliant.
3–7 Patients with quiescent UC who are
non-compliant with maintenance 5-ASA therapy
have been shown to have a fivefold greater risk of
disease flare-ups than compliant patients.
3
Increased disease activity impacts on patient health
and quality of life, may have economic conse-
quences through loss of productivity or earnings,
and results in increased hospitalisations, doctors
visits and drug costs.
8–13 In addition, regular 5-ASA
use may reduce the risk of developing colorectal
cancer,
14 either through decreased disease activ-
ity
15 16 or through a direct anticarcinogenic effect.
17
As compliance is such a major factor in disease
control,
4671 8it is important to understand what
drives non-adherence and what patients want from
their medication. In a recently published internet-
based survey of 1595 patients with UC receiving 5-
ASA therapy, reasons for poor compliance included
forgetting to take medication (stated by .90% of
patients), ‘‘too many pills’’, ‘‘dosing required too
many times each day’’, ‘‘medication too incon-
venient’’ and ‘‘no symptoms present’’,
19 confirming
the results of previous studies.
3 6 20 21 In the internet
survey, patients also expressed a wish for con-
venient, simple dosing regimens.
19 Nearly a quarter
(23%) of the patients surveyed considered fewer
pills and less frequent dosing as ‘‘very important’’
attributes when selecting a treatment for their
disease, and more than one-third (34%) considered
convenience to be very important. A mesalazine
preparation that involves the ingestion of fewer
tablets, less often, might therefore be considered
likely to impact favourably on compliance with
maintenance therapy.
In early 2007, mesalazine with MMX Multi
Matrix System (MMX) technology (Lialda (Shire
Pharmaceuticals Inc., Wayne, Pennsylvania, USA),
hereafter referred to as MMX mesalazine) was
approved in the USA for the induction of remission
of mild to moderate UC in a once-daily oral dose.
In Europe, MMX mesalazine (Mezavant XL in the
UK; Mezavant elsewhere in the EU) has been
approved for the induction and maintenance of
clinical and endoscopic remission in patients with
active, mild to moderate UC. This high-strength
formulation of 5-ASA (1.2 g tablet) utilises MMX
technology comprising lipophilic and hydrophilic
excipients enclosed within a gastro-resistant, pH-
dependent coating.
22 23 The gastro-resistant film,
covering the tablet core, delays the initial release of
5-ASA until the tablet is exposed to pH 7 or higher,
normally in the terminal ileum. As the gastro-
resistant coating disintegrates, it is thought that
intestinal fluids interact with the hydrophilic
excipient causing the tablet to swell (much like a
sponge in water) and form an outer viscous gel
mass. The viscous gel mass is believed to slow
diffusion of the 5-ASA from the tablet core into the
colonic lumen. As the tablet core and its surround-
ing gel mass progress through the colon, it is
thought that pieces of the gel mass gradually break
away from the core, releasing 5-ASA. It is supposed
that the lipophilic excipient slows the penetration
of aqueous fluids into the tablet core, reducing the
rate of dissolution and thus prolonging therapeutic
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coupled with the MMX drug delivery technology allows an
effective dose of 5-ASA to be delivered throughout the colon in a
single daily dose.
In two previous phase III, randomised, placebo-controlled
studies, by Lichtenstein et al
24 (SPD476-301) and Kamm et al
25
(SPD476-302), MMX mesalazine given as 2.4 g once daily, 1.2 g
twice daily or 4.8 g once daily was shown to be effective for the
induction of clinical and endoscopic remission in patients with
active, mild to moderate UC. To date, no data regarding the
long-term safety or efficacy of MMX mesalazine, or any other
oral 5-ASA, given once daily, have been published as a full
article. This study (SPD476-303 (clinical trial registry
web address as of 21 July 2007: http://www.clinicaltrial.gov/
ct/show/NCT00151944?order=1)) aimed to investigate
and compare the long-term safety and efficacy of mainte-
nanceMMXmesalazine2.4 g/day,giveneitherasaonce-dailyor
a twice-daily divided dose in patients with UC in remission.
METHODS
Patients
Male and female patients were entered into this maintenance
study following the induction of remission after an acute flare
of mild to moderate UC. Patients were enrolled directly
following up to 8 weeks’ treatment for acute disease, in the
studies reported by Lichtenstein et al and Kamm et al,
24 25
hereafter referred to as the ‘‘parent studies’’, or following a
further 8-week extension, study 303. Patients who achieved
clinical and endoscopic remission (defined as a modified UC
Disease Activity Index (UC-DAI) score of (1, with rectal
bleeding and stool frequency scores of 0; a combined
Physician’s Global Assessment (PGA) and sigmoidoscopy score
of (1, no mucosal friability and an additional requirement
for a >1-point reduction from baseline in sigmoidoscopy
score) during the parent studies could directly enter into the
12-month, randomised maintenance phase of this study.
Patients not in remission by the end of the parent studies,
and those who withdrew early after week 2, could enter an
8-week extension phase of study 303 and receive open-label
MMX mesalazine 4.8 g/day (2.4 g given twice daily) for
8 weeks. Patients in remission at the end of this 8-week
extension phase were then eligible to enter the randomised
maintenance phase.
Although not defined in the protocol, some additional
patients who were not in strictly defined remission (as above),
but deemed by their doctor to be well enough at the end of the
parent studies or the 8-week extension phase, could enter the
randomised maintenance phase of study 303.
All patients were required to have a satisfactory medical
assessment, with no clinically relevant abnormality other than
UC. Patients withdrawn from the parent studies, because of a
severe or serious adverse event (SAE), were not eligible. Co-
administration of corticosteroids (systemic or rectal), other
formulations containing 5-ASA, or immunosuppressants were
not permitted.
Thestudywasconducted inaccordance withcurrent applicable
regulations and Good Clinical Practice (GCP) guidelines, and
complied with the principles of the amended Declaration of
Helsinki. The institutional review board or ethics committee at
each site approved the protocol and subsequent amendments. All
patients gave written, informed consent.
Here we describe the study design and results for the
12-month, randomised maintenance phase.
Study design
Patients entering this 12-month maintenance study were
randomised via an interactive voice recognition system to
unblinded therapy with either MMX mesalazine 2.4 g/day
(given once daily) or MMX mesalazine 2.4 g/day (1.2 g given
twice daily). Patients entered through the two parent studies,
which recruited patients from 101 centres across 19 countries
(Australia (n=3), the Czech Republic (n=16), Estonia
(n=10), France (n=3), Germany (n=10), Hungary (n=31),
India (n=71), Israel (n=14), Latvia (n=9), Lithuania (n=14),
Mexico, including Costa Rica (n=18), New Zealand (n=12),
Poland (n=132), Romania (n=11), Russia (n=113), Spain
(n=7), the Ukraine (n=78) and the USA (n=71)). The
enrolment and treatment of patients during the current study
are summarised in fig 1.
Patients visited the clinic at month 0 (this visit was the same
as the end-of-study visit of the parent studies, or the end-of-
study visit of the 8-week extension phase of study 303), and
then at months 1, 3, 6, 9 and 12. At month 0, patients had: a
physical examination; haematology, biochemistry and urine
evaluation; sigmoidoscopy, symptoms assessment, PGA, drug
compliance check (by pill count), adverse event (AE) review and
concomitant medication review. Vital signs were also recorded
and, if applicable, a pregnancy test was performed. Patients
reported rectal bleeding and stool frequency symptoms (as
outlined by the modified UC-DAI) for the last available 3 days
prior to the visit. Data older than 5 days were not used.
Sigmoidoscopy was performed and inflammation scored in the
worst inflamed area in the rectum, or in the sigmoid colon if the
rectum was not inflamed.
During the clinic visits at months 1, 3, 6, 9 and 12 (or at the
early withdrawal visit), all of the above assessments were
carried out, excluding sigmoidoscopy and PGA, which were only
performed at the final study visit.
Primary objectives and outcomes
Given the lack of previous safety data for once-daily main-
tenance mesalazine therapy, including MMX mesalazine, the
pre-defined primary objective of this study was to assess the
safety and tolerability of the two dosage regimens over
12 months, including AEs, treatment exposure and time to
withdrawal.
All AEs were considered to be ‘‘treatment-emergent’’, as all
patients were being actively treated in the study. AEs were
defined as any untoward medical occurrence in a clinical
investigation subject who was administered a pharmaceutical
product and which did not necessarily have a causal
relationship with this treatment. It could, therefore, be any
unfavourable and unintended sign (including an abnormal
laboratory finding), symptom, disease or exacerbation of the
pre-existing condition temporally associated with the use of
the medication.
In addition, AEs could be defined as ‘‘treatment-related’’ and
were defined as either (1) possibly related to study drug (ie,
there may have been some temporal relationship between the
event and the administration of the investigational product but
there remained some ambiguity as to the cause) or (2) probably
related to study drug (ie, the temporal relationship between
the event and the administration of the investigational product
was compelling, and/or followed a known or suspected
response pattern to that product, and the event could not be
explained by the subject’s medical condition, other therapies or
accident).
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c Mild: the AE was easily tolerated and did not interfere with
usual activity
c Moderate: the AE interfered with daily activity but the
subject was still able to function
c Severe: the AE was incapacitating and the subject was
unable to work or complete usual activity.
SAEs were defined as any untoward medical occurrence
(whether considered to be related to the investigational product
or not) that at any dose: resulted in death; was life-threatening
(the subject was at risk of death at the time of the event);
required inpatient hospitalisation or prolongation of existing
hospitalisation; resulted in persistent or significant disability/
incapacity; or resulted in a congenital abnormality/birth defect.
Secondary objectives and outcomes
Predefined secondary outcome measures included comparisons
between the two treatment groups for: the proportion of
patients in remission (as defined in the parent studies (above))
at 12 months, and the components of the modified UC-DAI
score (eg, sigmoidoscopy score).
Figure 1 (A) Overall study design
(safety population) and (B) patient flow in
the 12-month, randomised, maintenance
phase of study SPD-476-303. *Patients
excluded from the efficacy population
because of study centre Good Clinical
Practice non-compliance.
{The ‘‘per-
protocol’’ population included only those
patients in the efficacy population who
met the strict protocol-defined criteria for
remission. AEs, adverse events;
SAEs, serious adverse events.
Inflammatory bowel disease
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patients taking >80% of their prescribed study medication were
considered compliant. Compliance with study medication was
calculated by pill count.
The UC-DAI (which comprises rectal bleeding, stool frequency,
sigmoidoscopyandPGA scores, each assessedon a scale of 0–3and
summed to give a total score of 0–12, as defined by Sutherland et
al
26) was modified in the parent studies and in this study, so that
patients who presented with mucosal friability were given a score
of 2 rather than 1. Using this amended scale, mucosal appearance
was graded according to the modified UC-DAI, where a score of
0 = normal; 1 (mild) = erythema, decreased vascular pattern
and minimal granularity; 2 (moderate) = marked erythema,
friability, granularity, absent vascular pattern, bleeding with
minimal trauma and no ulcerations; 3 (severe) = ulceration and
spontaneous bleeding. Thus, patients with any mucosal friability
were deemed not to be in remission. The PGA is a doctor-based
evaluation that considers the scores for rectal bleeding, stool
frequency and sigmoidoscopy together with the patient’s general
well-being and abdominal discomfort.
Study populations
The safety population was defined as all patients who received
at least one dose of study medication. The efficacy population
(‘‘intention-to-treat’’) consisted of all patients who received at
least one dose of study medication, other than those patients
coming from three study sites who, as previously described,
24
were excluded due to GCP non-compliance.
A retrospectively defined population, hereafter referred to as
the ‘‘per-protocol’’ population, included all patients in the
efficacy population who met the strict protocol-defined criteria
for remission (ie, excluded those patients who were not in
remission as defined by the protocol, but were enrolled in the
maintenance phase as they were deemed by their doctor to be
well enough to receive maintenance treatment).
Statistical analyses
This study was not designed as a clinical non-inferiority study
with minimally acceptable differences between the two treat-
ment regimens. The sample size was dependent on the number
of patients in clinical and endoscopic remission (defined above)
at the end of the parent studies, or at the end of the 8 weeks of
additional therapy with MMX mesalazine 4.8 g/day. As a result
of this design, no sample size calculation was performed.
Categorical values were summarised using frequencies and
percentages, and all statistical comparisons were considered
exploratory.
Relapse was defined as a requirement for alternative treat-
ment for UC, including surgery or an increase in the dose of
MMX mesalazine above 2.4 g/day. The proportion of patients
who were in remission at month 12 was compared between the
two treatment groups using the x
2 test. All safety summaries
were presented for the safety population. Adverse events were
coded using the Medical Dictionary for Regulatory Activities
(MeDRA) version 5.1. Time to withdrawal was analysed by
Kaplan–Meier methodology and measured from the date of the
first dose of study medication to the withdrawal date.
Treatment differences were analysed using a log-rank test.
RESULTS
Patient flow
The study was conducted between 26 November 2003 and
13 March 2006. A total of 459 patients (246 directly from the
parent studies and 213 patients who received an additional
8 weeks of treatment with MMX mesalazine 4.8 g/day) were
enrolled and randomised (fig 1A).
All patients were evaluable for safety. Eight patients (6 from
the once-daily group and 2 from the twice-daily group) were
excluded from the efficacy population because of non-compli-
ance and GCP issues. A further 89 patients were excluded from
the ‘‘per-protocol’’ population because they did not meet the
strict protocol-defined criteria for remission. Three hundred and
sixty-two patients were included in the ‘‘per-protocol’’ popula-
tion, 171 in the MMX mesalazine once-daily group and 191 in
the MMX mesalazine divided-dose group (fig 1B).
Overall, 182 (80.9%) patients in the once-daily group and 195
(83.3%) in the twice-daily group completed the study. The most
common reason for discontinuation in both dose groups was
lack of efficacy/relapse.
Patient demographics
Baseline demographic characteristics and UC history data were
similar for patients in both dose groups (table 1). There were no
clinically relevant differences between the two groups with
regard to the frequency and type of concomitant medication
taken during the study.
Safety
Extent of exposure
There was no difference between the two treatment groups
with regard to the mean (SD) duration of exposure to study
treatment (47.6 (11.1) weeks in the once-daily group and 47.6
(11.4) weeks in the twice-daily group). Although there was a
slight gradual decrease in retention (related to the clinical
relapse rate) over the 12-month treatment period, the retention
rate was in excess of 90% for the first 6 months and was almost
80% for the remainder of the study. The mean (SD) duration of
exposure to study treatment was also similar in patients
entering directly from the parent studies versus those entering
from the 8-week extension phase (48.4 (9.2) weeks vs 46.6
(13.2) weeks, respectively).
Treatment-emergent AEs
Overall, 174 patients (37.9%) experienced a total of 384 AEs, the
majority of which were mild or moderate in intensity. There
were no notable differences between treatment groups with
regard to the number and types of AE experienced (table 2). The
most frequent AEs were gastrointestinal disorders. Twelve
patients (2.6%) had 14 severe AEs. Most severe AEs were
gastrointestinal disorders (7 patients (1.5%)), which occurred to
a greater extent in the once-daily group (6 patients (2.7%)) than
the twice-daily group (1 patient (0.4%)). Only one SAE was
considered to be possibly or probably related to study treatment
(see below).
Treatment-related AEs
Forty-seven patients (10.2%) experienced 76 treatment-related
AEs. There were no notable differences between treatment
groups with regard to the number and type of treatment-related
AEs (table 2). The most frequent treatment-related AEs were
gastrointestinal disorders.
SAEs
Eighteen patients (3.9%), nine in each group, experienced a total
of 22 SAEs (10 in the once-daily group and 12 in the twice-daily
group) (table 2). Most SAEs were gastrointestinal disorders,
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group and 4 (1.7%) in the twice-daily group. One SAE
(abnormal liver function tests) in the once-daily group was
assessed as possibly related to treatment, leading to the patient
being withdrawn from the study at the month 1 visit. This
patient was noted to have elevated alkaline phosphatase (ALP;
138 U/l; normal range 31–121 U/l), aspartate transaminase
(AST; 561 U/l; normal range 1–32 U/l) and alanine amino-
transferase (ALT; 1058 U/l) values at month 1. Viral screening
revealed a positive latex test for infectious mononucleosis.
Discontinuations due to AEs
Twenty-one patients (4.6%) experienced 23 AEs that led to
withdrawal (11 patients (4.9%) in the once-daily group and 10
patients (4.3%) in the twice-daily group). Most AEs that led to
withdrawal were gastrointestinal disorders (9 (4.0%) patients in
the once-daily group and 6 (2.6%) in the twice-daily group).
Eleven patients were withdrawn due to SAEs (5 patients in the
once-daily group and 6 in the twice-daily group). One patient
died due to electric shock.
Time to withdrawal
There was no significant difference (p=0.62) between the two
groups in relation to the time to withdrawal, with a small and
gradual decrease in retention rate being observed over the 12-
month treatment period. The retention rate was in excess of
90% for the first 6 months of the maintenance phase and was in
excess of 80% for the remainder of the study.
Other safety parameters
There were no remarkable changes in vital signs or clinical
laboratory parameters in either treatment group.
Remission
Overall remission
In the efficacy population, 78.1% of patients in the once-daily
group and 82.3% of patients in the divided-dose group were in
clinical and endoscopic remission at entry (month 0) according
to the strict criteria employed in this study (fig 2). At month 12,
64.4% of patients in the once-daily group and 68.5% of patients
in the divided-dose group were in strictly defined clinical and
endoscopic remission (fig 2). There was no significant difference
between the two treatment groups (p=0.351, odds ratio (OR)
0.83 (95% CI 0.56 to 1.23)).
In the ‘‘per-protocol’’ population in which, by definition,
100% of patients in both groups met the strict remission criteria
at month 0, endoscopic and clinical remission were maintained
at month 12 in 67.8% of patients in the once-daily group and
72.3% of patients in the divided-dose group (p=0.359, OR 0.81
(95% CI 0.52 to 1.27)).
Remission by entry route and previous treatment in the parent
studies
In the efficacy population, of those patients who entered the
maintenance phase directly via the parent studies, 75.8% were
in remission at month 12 compared with 55.9% of patients who
entered via the 8-week extension phase (p,0.0001). Similar
results were seen in the ‘‘per-protocol’’ population (80.7% vs
59.7%, respectively; p,0.0001).
In the efficacy population, remission rates for both dosing
regimens were similar for patients entering via the parent
studies (74.6% once daily vs 77.0% twice daily, p=0.655, OR
0.87 (95% CI 0.48 to 1.58)) or via the 8-week extension study,
(52.5% once daily vs 59.1% twice daily, p=0.334, fig 3).
Similarly, in the ‘‘per-protocol’’ population, remission rates for
both dosing regimens were similar for patients entering via the
Table 1 Demographics and baseline characteristics on entry into the parent studies (safety population)
MMX mesalazine 2.4 g/day
(given once daily) (n=225)
MMX mesalazine 2.4 g/day (1.2 g
given twice daily) (n=234)
Male n (%) 106 (47.1) 114 (48.7)
Mean (SD) age, years 42.4 (12.1) 42.6 (13.2)
Non-/previous smoker, n (%) 213 (94.7) 215 (91.9)
Caucasian, n (%) 193 (85.8) 202 (86.3)
Diagnosis, n (%)
Newly diagnosed 32 (14.2) 34 (14.5)
History of UC 193 (85.8) 200 (85.5)
Mean (SD) time since diagnosis, weeks 244.5 (314.1) 288.4 (338.8)
Relapses in last 2 years, n (%)
0–2 135 (60.0) 144 (61.5)
3–6 76 (33.8) 82 (35.0)
>7 4 (1.8) 5 (2.1)
Missing 10 (4.4) 3 (1.3)
Classification of disease*, n (%)
Left-sided 175 (77.8) 179 (76.5)
Upper limit in transverse colon 14 (6.2) 14 (6.0)
Pancolitis 36 (16.0) 40 (17.1)
Baseline modified UC-DAI score (at parent study entry),
mean (SD)
6.3 (1.5) 6.5 (1.4)
Treatment received in parent studies, n (%)
Placebo 57 (25.3) 61 (26.1)
MMX mesalazine 2.4 g/day 68 (30.2) 67 (28.6)
MMX mesalazine 4.8 g/day 72 (32.0) 70 (29.9)
Asacol 28 (12.4) 36 (15.4)
*Based on patient disease history.
UC, ulcerative colitis; UC-DAI, UC Disease Activity Index.
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patients, respectively, in any treatment group in the safety population
Number (%) of patients
MMX mesalazine 2.4 g/day (given
once daily) (n=225)
MMX mesalazine 2.4 g/day (1.2 g
given twice daily) (n=234)
Any AE 88 (39.1) 86 (36.8)
Aggravated UC 24 (10.7) 18 (7.7)
Abdominal pain (NOS) 5 (2.2) 4 (1.7)
Abdominal pain upper 1 (0.4) 5 (2.1)
Nasopharyngitis 3 (1.3) 5 (2.1)
Pharyngitis 5 (2.2) 2 (0.9)
Headache 2 (0.9) 5 (2.1)
Any mild AE 62 (27.6) 63 (26.9)
Any moderate AE 44 (19.6) 38 (16.2)
Any severe AE 7 (3.1) 5 (2.1)
Any SAE 9 (4.0) 9 (3.8)
Any AE leading to withdrawal 11 (4.9) 10 (4.3)
Any AE leading to death 0 (0.0) 1 (0.4)
Any treatment-related AE 25 (11.1) 22 (9.4)
Abdominal pain (NOS) 3 (1.3) 2 (0.9)
Colitis ulcerative aggravated 4 (1.8) 1 (0.4)
Diarrhoea (NOS) 3 (1.3) 2 (0.9)
Abdominal pain upper 1 (0.4) 3 (1.3)
Summary of SAEs
Angina pectoris 0 1
Pulmonary oedema 0 1
UC 5 4
Chronic hepatitis 1 0
Lung abscess 0 1
Pneumonia 0 2
Electric shock 0 1
Abnormal liver function test 1 0
Cerebral infarction 1 0
Aggravated depression 0 1
Menometrorrhagia 1 0
Ovarian cyst 1 0
COPD exacerbation 0 1
AE, adverse event; COPD, chronic obstructive pulmonary disease; NOS, not otherwise specified; SAE, serious adverse event;
UC, ulcerative colitis.
Figure 2 Remission rates at month 0 and month 12 in the efficacy and
‘‘per-protocol’’ populations following treatment with MMX mesalazine
2.4 g/day given once daily or twice daily.
Figure 3 Remission rates at month 0 and month 12 by study entry
route (8-week extension phase of study 303 or parent studies) in the
efficacy population following treatment with MMX mesalazine 2.4 g/day
given once daily or twice daily.
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p=0.869) or via the 8-week extension phase (54.7% once daily
vs 64.2% twice daily; p=0.190).
Patients’ remission rates, stratified by the treatment received
in the parent studies, are shown in table 3.
Remission rates for patients who did not meet strict entry criteria at
baseline (n=89)
Eighty-nine patients entered the maintenance phase of this
study who were not in strictly defined clinical and endoscopic
remission at baseline, but who were considered to be well
enough by their treating doctor. Their remission rates were less
than those achieved by the intention-to-treat population as a
whole. Of these 89 patients, remission rates at 12 months were
similar between patients dosed once daily (52.1% (25/48
patients)) or twice daily (51.2% (21/41 patients) p=0.935).
Of these patients, those who entered the maintenance phase
through the 8-week extension phase, there was no significant
difference between the two treatment groups in relation to
endoscopic and clinical remission (40% once daily (6/15
patients) vs 26.7% twice daily (4/15 patients) p=0.44).
Similar numbers of patients who entered the maintenance
phase directly from the parent study were in remission at
12 months irrespective of maintenance therapy dose regimen
(57.6% once daily (19/33 patients) vs 65.4% twice daily (17/26
patients) p=0.541).
Relapse rates
At 12 months, the proportion of patients in the efficacy
population who had not relapsed was 88.9% in the once-daily
group and 93.2% in the twice-daily group. Similarly, in the ‘‘per-
protocol’’ population, the proportion of patients who had not
relapsed at 12 months was 88.7% in the once-daily group and
92.5% in the twice-daily group.
Mucosal appearance
The degree of mucosal inflammation at parent study baseline,
upon entry to the maintenance phase and at 12 months is
shown in table 4 for the efficacy and ‘‘per-protocol’’ popula-
tions. In both populations, the majority of patients in both
treatment groups had a moderately inflamed mucosal appear-
ance (median sigmoidoscopy score of 2) at parent study
baseline. At entry to the maintenance study, the majority of
patients in both groups had a normal mucosal appearance
(sigmoidoscopy score of 0), with the remainder having a
sigmoidoscopy score of 1. At month 12, these sigmoidoscopy
scores had largely been maintained; in the efficacy population,
approximately 78% of patients had a sigmoidoscopy score of 0
or 1, while in the ‘‘per-protocol’’ population, approximately
81% of patients had a sigmoidoscopy score of 0 or 1. For both
the efficacy and ‘‘per-protocol’’ populations, there were no
apparent differences between the two dosing regimens in the
distribution of sigmoidoscopy scores after 12 months’ therapy.
Compliance
No notable differences in compliance rates were observed
between treatment groups (safety population) at any visit.
Overall, 442 (96.3%) patients took >80% of their prescribed
study medication (93.3% in the once-daily group and 99.6% in
the twice-daily group).
DISCUSSION
This study is the first to describe the safety and efficacy of
MMX mesalazine administered once or twice daily for the
maintenance of remission of UC, over a period of 12 months.
To our knowledge, to date no data have been published in a full
article regarding the long-term safety of once-daily 5-ASA use or
long-term use of MMX technology. MMX mesalazine 2.4 g/day
(given once daily or 1.2 g twice daily) was shown to be well
tolerated over the 12-month period. The withdrawal rate was
very low, with a .80% retention rate at 12 months. During
12 months of treatment, AEs and treatment-related AEs were
infrequent, generally mild to moderate in intensity, and
gastrointestinal in nature (most commonly related to the
underlying condition). Severe AEs, most commonly gastro-
intestinal events, were also rare. While a greater number of
severe AEs were reported in the once-daily group, no severe AE
in either dose group was considered to be related to study
medication. Only one SAE (abnormal liver function tests) was
considered possibly related to treatment. Although the current
study did not include a placebo arm, the AE profile reported here
is similar to those reported in long-term studies of other non-
sulphur-containing 5-ASA formulations, where AEs were also
infrequently reported, usually of mild to moderate severity and
mainly gastrointestinal in nature.
27–36 The safety results of the
present study also support the results of a recent meta-analysis
of prospective, randomised, double-blind, and controlled trials
of newer release 5-ASA formulations showing that long-term 5-
ASA use incurs no more AEs than placebo.
37 Pancreatitis, a
known idiosyncratic side effect of mesalazine, was seen in one
of the parent studies,
24 but not seen in this maintenance study,
presumably because patients were stable on the medication and
because of its rarity.
Table 3 Summary of patients in remission at month 12 stratified by previous treatment and entry route (efficacy population; n=451)
Treatment in parent studies Entry route into maintenance phase
Patients in remission at the end of 12 months, n (%)
MMX mesalazine 2.4 g/day
Total 2.4 g given once daily (n=225) 1.2 g given twice daily (n=234)
Placebo Direct 18/22 (81.8) 16/20 (80.0) 34/42 (81.0)
Via 8-week extension 19/34 (55.9) 25/41 (61.0) 44/75 (58.7)
MMX mesalazine 2.4 g/day* Direct 25/37 (67.6) 33/42 (78.6) 58/79 (73.4)
Via 8-week extension 14/29 (48.3) 13/24 (54.2) 27/53 (50.9)
MMX mesalamine 4.8 g/day Direct 30/42 (71.4) 32/41 (78.0) 62/83 (74.7)
Via 8-week extension 15/27 (55.6) 17/28 (60.7) 32/55 (58.2)
Asacol 2.4 g/day{ Direct 15/17 (88.2) 13/19 (68.4) 28/36 (77.8)
Via 8-week extension 5/11 (45.5) 10/17 (58.8) 15/28 (53.6)
*Patients received MMX mesalazine 2.4 g/day given once daily in the Kamm study,
25 and as 1.2 g twice daily in the Lichtenstein study.
24 {Patients received Asacol 2.4 g/day (given
as 0.8 g three times daily) as a reference arm in study 302 only.
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daily maintenance therapy has not been published. In this
study, the pre-specified end points included the long-term
efficacy. MMX mesalazine maintained clinical and endoscopic
remission over the 12-month study period in 64.4 and 68.5% in
the once-daily and divided-dose groups, respectively. This
remission rate refers to those patients who had experienced
no flare-up during the study and fulfilled the other strict
remission criteria, including endoscopic remission.
Approximately 20% of patients who entered into the
maintenance study were not in remission (as defined by the
strict criteria in the protocol) at month 0, but were deemed well
enough by individual investigators to receive maintenance
therapy. When these patients were excluded from the analyses,
strictly defined clinical and endoscopic remission rates of
approximately 70% were observed at month 12.
The remission rates for those not in full endoscopic and
clinical remission were less than those achieved by the
intention-to-treat populations as a whole, suggesting that full
endoscopic and clinical remission at entry were more likely to
result in maintained remission at 12 months.
As well as maintaining strict clinical and endoscopic remis-
sion, very few patients relapsed while receiving MMX mesala-
zine—that is, 12% of patients in the once-daily group and 8% of
patients in the twice-daily group (all evaluable patients). There
was also no significant difference between the two dosing
regimens with regards to time to relapse. The study population
comprised patients who had experienced a disease flare-up
immediately prior to entering the maintenance study (ie, were
part of the active disease parent studies). Such a population
might be expected to contain more patients who will subse-
quently relapse than a study population consisting of patients
who have been in remission for a long time.
38
The design of the trials with MMX measalazine has allowed
investigation of the same study population through both
induction and subsequent maintenance of UC remission with
MMX mesalazine. The study population enrolled in this 303
maintenance trial was therefore characterised by a good
response to mesalazine in the parent induction of remission
trials. These patients may be more mesalazine responsive than
the total population of colitic patients. The results presented
here have shown that patients receiving MMX mesalazine and
patients who received Asacol (internal reference arm of the
Kamm study
25) during the parent studies had similar 12-month
remission rates following maintenance therapy with MMX
mesalazine. Therefore, MMX mesalazine appears to be effica-
cious as maintenance therapy regardless of the 5-ASA formula-
tion used to induce remission.
Overall, 5-ASA formulations have been shown to be generally
effective for maintenance of UC remission. In a meta-analysis of
oral 5-ASA formulations for the maintenance of remission of
UC, the Peto OR for the failure to maintain clinical or
endoscopic remission for oral 5-ASA versus placebo was 0.47
(95% CI, 0.36 to 0.62).
37 However, long-term (.6 months)
remission rates, and clinical and endoscopic response rates,
reported in previous studies vary considerably. For example, in a
12-month, randomised, follow-up study of 80 patients with
quiescent UC receiving oral mesalazine 2.4 g/day, only 30% of
patients were in remission at the end of the study.
39 In contrast,
a double-blind, randomised study comparing oral controlled-
release mesalazine 4 g/day (Pentasa
H; available from Shire
Pharmaceuticals, Wayne, Pennsylvania, USA) with placebo
demonstrated that after 12 months, 64% and 38% of patients,
respectively, had not relapsed (defined by endoscopic appear-
ance, stool frequency and the presence of rectal bleeding), and
thus were considered to be in remission.
27
The variability in reported remission rates is, in part, due to
the diverse range of clinical and endoscopic indices utilised by
the investigators in such studies, and the subsequent variability
in the definition of remission. For instance, the recent PODIUM
(Pentasa Once Daily In Ulcerative colitis for Maintenance of
remission) trial defined remission as a UC-DAI score of ,2.
40 In
the present study remission was defined as a UC-DAI score of
(1. In the original UC-DAI, mucosal friability is allowed at a
score of 1; however, for additional stringency, we excluded any
patient with mild mucosal friability on endoscopy. This is
important as recently published data suggest that those patients
who achieve mucosal healing are less likely to relapse than those
who do not.
41 Moreover, the presence of macroscopic large
bowel inflammation has also been shown to be an important
independent determinant of the risk of colorectal neoplasia in
patients with long-standing UC.
15 It is clear that the clinical
relevance of trial end points should be considered when
validating claims regarding efficacy and dosing regimens.
Table 4 Sigmoidoscopy score distribution at parent study baseline, upon entry to the maintenance phase (month 0) and at 12 months
Sigmoidoscopy score
MMX mesalazine 2.4 g/day (given once daily) MMX mesalazine 2.4 g/day (1.2 g given twice daily)
Efficacy population n=219
(% patients)
‘‘Per-protocol’’ population
n=171 (% patients)
Efficacy population n=232
(% patients)
‘‘Per-protocol’’ population
n=191 (% patients)
Parent study baseline
0 (normal) 0000
1 (mild) 18.7 18.1 12.5 11.5
2 (moderate) 74.9 77.2 80.6 81.7
3 (severe) 6.4 4.7 6.9 6.8
Month 0
0 (normal) 66.2 66.1 58.6 59.7
1 (mild) 33.8 33.9 41.4 40.3
2 (moderate) 0000
3 (severe) 0000
Month 12
0 (normal) 57.1 58.5 56.9 59.7
1 (mild) 21.5 22.2 21.6 20.9
2 (moderate) 3.2 2.9 3.4 2.6
3 (severe) 0.5 0 1.7 2.1
missing 17.8 16.4 16.4 14.7
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Results obtained from the ITT population and the ‘‘per-
protocol’’ populations were similar, indicating that patients who
did not fully achieve remission during the parent trials could still
achieve and maintain clinical and endoscopic remission when
receiving MMX mesalazine as maintenance therapy at a dose of
2.4 g/day. This is a reassuring result, as in clinical practice a doctor
may consider a patient to be in remission without performing an
endoscopy. Remission rates at 12 months with MMX mesalazine
were higher in patients who entered the maintenance study
directly from the parent studies compared with those whoentered
via the 8-week extension phase of study 303. This suggests that
patients able to achieve remission with MMX mesalazine during
an 8-week period may represent a more mesalazine-responsive
patient population, relative to those who required an additional
8 weeks of treatment. Moreover, our findings suggest that
patients who are more quickly responsive during therapy for
achieving remission may be more likely to be maintained in
remission during MMX mesalazine maintenance therapy.
Maintenance therapy of remission with MMX mesalazine was
associated with favourable endoscopic findings, such that, at
month 12, the majority of patients in both treatment groups
(57%) had a normal mucosal appearance. The vast majority of the
remaining patients with available severity data (.80%), in either
treatment group, had a sigmoidoscopy score of only 1 at month
12, and only a very small percentage of patients (,1.5%) had a
worsened mucosal appearance from parent study baseline. Very
similar observations were made in the ‘‘per-protocol’’ population.
Despite the long duration of the study, 93.3% of patients in
the once-daily group and 99.6% of patients in the twice-daily
group were >80% compliant with the study medication. While
the compliance rate was extremely high, it was not unexpected
given the fact that patients were closely monitored in a clinical
trial environment, where compliance rates are traditionally
high. However, the disparity between compliance rates in
controlled trials and the community setting is well known.
20 It
remains to be seen if the compliance rates achieved in the
present study will translate into improved compliance in general
clinical practice compared with the standard multiple daily
dose, high tablet burden, 5-ASA regimens currently in use.
The current study did not include a placebo arm. When
designing the study such a placebo comparison was considered
unethical, given the established efficacy and low toxicity of 5-ASA
therapy in maintaining remission. The high clinical remission
(relapse free) rate seen in this study is substantially greater than
seeninpreviousearlyplacebo-controlledandobservationalstudies.
In summary, once-daily MMX mesalazine appears to have a
similar safety and efficacy profile to twice-daily MMX
mesalazine, in the maintenance of remission of ulcerative colitis.
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Robin Spiller, editor
An unexpected cause of chronic
diarrhoea
CLINICAL PRESENTATION
A 41-year-old man suffered from chronic diarrhoea of 3
years’ duration, accompanied by weight loss of 20 kg. He
was referred to our hospital for double-balloon enteroscopy
(DBE). On arrival, the laboratory findings were as follows:
haemoglobin 10.4 g/dl (normal range 12.0–16.0 g/dl) and
albumin 2.9 g/dl (normal range 3.5–5.3 g/dl). DBE was
performed via the oral route and reached the middle
jejunum. Several irregularly shaped ulcerations, up to 1 cm
in size, were found at the gastric antrum and duodenum.
Moreover, the jejunal mucosa appeared diffusely whitish,
streaky and granular, resembling the texture of marble
(fig 1A,B). Severe atrophy of the normal intestinal villi was
also noted.
QUESTION
What is your diagnosis?
See page 921 for the answer.
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Figure 1 (A) Marbled appearance of the
‘‘white small intestine’’ with diffuse
polypoid lesions at the jejunum. (B) In a
closer view, atrophy of the villi and
diffuse whitish streaks on the lesions
were noted.
Editor’s quiz: GI snapshot
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